Campbell Rogers, M.D., F.A.C.C.

AIMBE College of Fellows Class of 2005
For contributions to the development and scientific evaluation of implantable devices through linkage of biomedical engineering, innovation and cardiovascular disease.

HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests

Via Globe News Wire | May 22, 2018

HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests. Additionally, data from the SYNTAX III Revolution trial demonstrated the utility of the HeartFlow Analysis combined with coronary computed tomography angiography (CTA) in helping clinicians make revascularization treatment decisions (stenting or coronary bypass surgery) for patients with multi-vessel disease. The non-invasive HeartFlow Analysis is a personalized cardiac test that aids clinicians in identifying the right treatment pathway for each patient. The results of both trials were presented during the EuroPCR Conference in Paris, France.

The PACIFIC trial included 208 patients who each underwent a coronary computed tomography angiography (CTA), SPECT, PET and routine three-vessel invasive fractional flow reserve (FFR) measurements. The HeartFlow Analyses were retrospectively obtained from the coronary CTA images. On a per vessel basis, HeartFlow demonstrated significantly greater diagnostic performance (0.94 as measured by area under the receiver operating characteristic curve) compared to coronary CTA (0.83, p<0.001), SPECT (0.70, p<0.001) and PET (0.87, p<0.001). The results of this head-to-head study were presented by Dr. Roel Driessen of the VU University Medical Center. Paul Knaapen, M.D., Ph.D. was the principal investigator of the PACIFIC trial… Continue reading.